Organovo initiated with a Buy at H.C. Wainwright. H.C. Wainwright analyst Ed Arce started Organovo Holdings with a Buy rating and $2.50 price target. Though early, the therapeutic tissue opportunity is compelling, Arce tells investors in a research note. The analyst views Organovo as the “clear leader in the early, pioneering technology of 3D bioprinting of solid organs.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.